1. Novel targeted therapies for eosinophilic disorders
Michael E. Wechsler, MD, MMSc, Patricia C. Fulkerson, MD, PhD, Bruce S. Bochner, MD, Gail M. Gauvreau, PhD, Gerald J. Gleich, MD, Tim Henkel, MD, PhD, Roland Kolbeck, PhD, Sameer K. Mathur, MD, PhD, Hector Ortega, MD, ScD, Jatin Patel, MD, Calman Prussin, MD, Paolo Renzi, MD, Marc E. Rothenberg, MD, PhD, Florence Roufosse, MD, PhD, Dagmar Simon, MD, Hans-Uwe Simon, MD, PhD, Andrew Wardlaw, MD, Peter F. Weller, MD, Amy D. Klion, MD 
Journal of Allergy and Clinical Immunology 
Volume 130, Issue 3, Pages (September 2012)
DOI: /j.jaci
Copyright © Terms and Conditions

2. Fig 1
Active and theoretic eosinophil-selective therapeutic targets. The eosinophil possesses multiple targets that are the focus of active research in patients with hypereosinophilic diseases. These include IL-5, CCR3, Siglec-8, EMR1, CRTH2, cysteinyl leukotriene 1 (CYSLTR1), and the glucocorticoid receptor (GR). Multiple other targets on the eosinophil and in pathways indirectly related to the eosinophil exist and are not depicted in this image. Medical Illustrator Jacqueline Schaffer provided this work.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © Terms and Conditions